[HTML][HTML] Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …
[HTML][HTML] Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …
[HTML][HTML] The renaissance of cyclin dependent kinase inhibitors
T Ettl, D Schulz, RJ Bauer - Cancers, 2022 - mdpi.com
Simple Summary This review provides an overview of the state of knowledge and general
understanding of CDK inhibitors currently under development or clinically approved, with a …
understanding of CDK inhibitors currently under development or clinically approved, with a …
[HTML][HTML] DNA damage response mechanisms in head and neck cancer: significant implications for therapy and survival
C Papalouka, M Adamaki, P Batsaki… - International Journal of …, 2023 - mdpi.com
Head and neck cancer (HNC) is a term collectively used to describe a heterogeneous group
of tumors that arise in the oral cavity, larynx, nasopharynx, oropharynx, and hypopharynx …
of tumors that arise in the oral cavity, larynx, nasopharynx, oropharynx, and hypopharynx …
[HTML][HTML] Combination therapy as a promising way to fight oral cancer
Oral cancer is a highly aggressive tumor with invasive properties that can lead to metastasis
and high mortality rates. Conventional treatment strategies, such as surgery, chemotherapy …
and high mortality rates. Conventional treatment strategies, such as surgery, chemotherapy …
[HTML][HTML] Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?
C Riess, N Irmscher, I Salewski, D Strüder… - Cancer and Metastasis …, 2021 - Springer
Cyclin-dependent kinases (CDK) control the cell cycle and play a crucial role in
oncogenesis. Pharmacologic inhibition of CDK has contributed to the recent clinical …
oncogenesis. Pharmacologic inhibition of CDK has contributed to the recent clinical …
Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting
Regulated cell division is one of the fundamental phenomena which is the basis of all life on
earth. Even a single base pair mutation in DNA leads to the production of the dysregulated …
earth. Even a single base pair mutation in DNA leads to the production of the dysregulated …
[HTML][HTML] An O-GlcNAcylomic Approach Reveals ACLY as a Potential Target in Sepsis in the Young Rat
M Denis, T Dupas, A Persello, J Dontaine… - International Journal of …, 2021 - mdpi.com
Sepsis in the young population, which is particularly at risk, is rarely studied. O-
GlcNAcylation is a post-translational modification involved in cell survival, stress response …
GlcNAcylation is a post-translational modification involved in cell survival, stress response …
Protein O‐GlcNAcylation levels are regulated independently of dietary intake in a tissue and time‐specific manner during rat postnatal development
T Dupas, M Denis, J Dontaine, A Persello… - Acta …, 2021 - Wiley Online Library
Aim Metabolic sources switch from carbohydrates in utero, to fatty acids after birth and then a
mix once adults. O‐GlcNAcylation (O‐GlcNAc) is a post‐translational modification …
mix once adults. O‐GlcNAcylation (O‐GlcNAc) is a post‐translational modification …
Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial
P Oppelt, JC Ley, F Worden, K Palka, R Maggiore, J Liu… - Oral Oncology, 2021 - Elsevier
Objectives We previously reported that palbociclib, a selective CDK4/6 inhibitor, given with
cetuximab, resulted in an objective response rate (ORR) of 19% in cetuximab-resistant …
cetuximab, resulted in an objective response rate (ORR) of 19% in cetuximab-resistant …